Galapagos announces appointment of Howard Rowe to Board of Directors, increases share capital through warrant exercises

09-Sep-2010 - Belgium

Galapagos NV announced that its Board of Directors has appointed Mr. Howard Rowe as an Independent Director of the Company. Furthermore, Galapagos announced a capital increase arising from employee warrant exercises.

Howard Rowe (41) was previously a Managing Director with Goldman Sachs where he had multiple Healthcare responsibilities over his 12 years at the firm. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. During that time he served on the boards of EUSA Pharma, Healthcare Brands International, MedAvante, SmallBone Innovations and Ikonisys. Prior to his investing activities, Mr. Rowe was a senior member of the European Healthcare Investment Banking team, where he advised numerous corporate clients on M&A and corporate finance activities. Before joining Goldman Sachs, he was a corporate lawyer with the law firm Sullivan & Cromwell. Mr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California, and his JD from Harvard Law School.

Mr. Rowe's appointment as a Board Member is for a period until the 2011 annual shareholders' meeting. He is an Independent Director and also is appointed as a member of the Remuneration Committee. This appointment fills the vacancy created by Dr. Garth Rapeport's resignation from the Board in June 2010.

Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in August 2010, Galapagos issued 3,442 new ordinary shares on 7 September 2010 for a total capital increase, including issuance premium, of €29,913.90, or an average of €8.69 per new share. No member of the Board or Executive Committee exercised warrants. Following today's capital increase, Galapagos now has a share capital amounting to €129,252,393.80, with a total of 23,893,480 ordinary shares outstanding. There are no other voting securities.

https://www.bionity.com/en/news/122644/galapagos-announces-appointment-of-howard-rowe-to-board-of-directors-increases-share-capital-through-warrant-exercises.html